ArticleFrontiers in cardiovascular medicine2026
Biochanin A attenuates doxorubicin-induced cardiotoxicity in rats with associated modulation of PI3K/Akt/mTOR and p38 MAPK signaling.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biochanin A ameliorates vancomycin-induced acute kidney injury via modulation of the JAK2/STAT-3/GPX4 axis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Doxorubicin (DOX) is an effective anthracycline chemotherapeutic agent, but its clinical use is limited by dose-dependent cardiotoxicity associated with oxidative stress, inflammation, and apoptosis. Biochanin A (BCA), an O-methylated isoflavone, has demonstrated antioxidant and anti-inflammatory properties. Objectives: This study investigated whether BCA could mitigate DOX-induced cardiac injury in rats and explored the underlying molecular mechanisms. Methods: Male Wistar rats were randomly assigned to control, BCA-alone, DOX-alone, and DOX combined with BCA (25 or 50 mg/kg) groups. Cardiotoxicity was induced by DOX administration. Electrocardiographic (ECG) parameters were recorded, and serum cardiac biomarkers (CK-MB, LDH, and troponin) were measured. Cardiac tissue was evaluated for oxidative stress markers, antioxidant enzyme activities, inflammatory mediators, and apoptotic gene expression. Histopathological examination was performed. The involvement of PI3K/Akt/mTOR, p38 MAPK, and PTEN signaling pathways was assessed using molecular analyses. Results: DOX administration caused significant ECG abnormalities, elevated serum cardiac biomarkers, increased lipid peroxidation, reduced antioxidant enzyme activities, enhanced inflammatory cytokine levels, and upregulated pro-apoptotic markers in cardiac tissue. Histological examination revealed marked myocardial degeneration. BCA treatment attenuated these alterations, with greater effects observed at the higher dose in several endpoints. It was associated with improved antioxidant status, reduced inflammatory and apoptotic marker expression, decreased p38 MAPK and PTEN immunoreactivity, and was associated with altered PI3K/Akt/mTOR and p38 MAPK pathway-marker immunoreactivity compared with the DOX group. Conclusions: Biochanin A alleviated acute DOX-induced cardiotoxicity in rats and was associated with modulation of oxidative stress, inflammatory, apoptotic markers, as well as, PI3K/Akt/mTOR and p38 MAPK pathway markers. BCA may therefore represent a potential cardioprotective adjunct strategy in acute anthracycline-associated cardiac injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.